National Storage Mechanism | Additional information
RNS Number : 9868K
Societe Generale SA
27 April 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

                         Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.0001 ordinary shares

Date of dealing

24/04/2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

3,570,643

1.08

46,034

0.01

(2) Derivatives (other than options)

0

0.00

3,283,991

1.00

(3) Options and agreements to purchase/sell

58,500

0.02

0

0.00

Total

 

*9,583,036

 

*2.91

3,330,025

1.01

                               

* Include the holding of 5,953,893 shares on borrow products

               

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

53

186.9

Purchase

17

186.24

Purchase

100

186.46

Purchase

100

186.56

Purchase

600

186.9

Purchase

100

186.65

Purchase

100

186.68

Purchase

200

186.515

Purchase

100

186.495

Purchase

100

186.55

Purchase

100

185.86

Purchase

100

185.25

Purchase

100

185.78

Purchase

100

185.505

Purchase

100

185.5

Purchase

100

186.57

Purchase

100

185.285

Purchase

100

185.43

Purchase

66

186.63

Purchase

100

185.47

Purchase

100

186.54

Purchase

91

185.42

Purchase

1,576

186.9

Purchase

19

186.542526

Sale

72

186.89125

Sale

100

185.87

Sale

100

185.31

Sale

1

185.77

Sale

99

185.76

Sale

100

185.77

Sale

42

186.895

Sale

100

186.36

Sale

59

186.9

Sale

100

186.11

Sale

15

186.42

Sale

100

185.41

Sale

100

186.9

Sale

5,943

186.9

Sale

100

185.76

Sale

100

186.3

Sale

100

186.55

Sale

985

186.9

Sale

2,955

186.9

Total Purchases

4,222

 

Total Sales

11,171

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

 

Date of disclosure

27/04/2020

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

 

 

Ap23

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

 

 

Product name,

e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Listed Put Option

Sale

40,000

175

American options

15/01/2021

Listed Put Option

Sale

18,500

190

American options

15/01/2021

 

 

Notes

 

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.          For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISESEIFSWESSEIL